Literature DB >> 19737886

Retinal nerve fiber layer thickness measurement comparability between time domain optical coherence tomography (OCT) and spectral domain OCT.

Jong S Kim1, Hiroshi Ishikawa, Michelle L Gabriele, Gadi Wollstein, Richard A Bilonick, Larry Kagemann, James G Fujimoto, Joel S Schuman.   

Abstract

PURPOSE: Time domain optical coherence tomography (TD-OCT) has been used commonly in clinical practice, producing a large inventory of circular scan data for retinal nerve fiber layer (RNFL) assessment. Spectral domain (SD)-OCT produces three-dimensional (3-D) data volumes. The purpose of this study was to create a robust technique that makes TD-OCT circular scan RNFL thickness measurements comparable with those from 3-D SD-OCT volumes.
METHODS: Eleven eyes of 11 healthy subjects and 7 eyes of 7 subjects with glaucoma were enrolled. Each eye was scanned with one centered and eight displaced TD-OCT scanning circles. One 3-D SD-OCT cube scan was obtained at the same visit. The matching location of the TD-OCT scanning circle was automatically detected within the corresponding 3-D SD-OCT scan. Algorithm performance was assessed by estimating the difference between the detected scanning circle location on 3-D SD-OCT volume and the TD-OCT circle location. Global and sectoral RNFL thickness measurement errors between the two devices were also compared.
RESULTS: The difference (95% confidence interval) in scanning circle center locations between TD- and SD-OCT was 2.3 (1.5-3.2) pixels (69.0 [45.0-96.0] microm on the retina) for healthy eyes and 3.1 (2.0-4.1) pixels (93.0 [60.0-123.0] microm on the retina) for glaucomatous eyes. The absolute RNFL thickness measurement difference was significantly smaller with the matched scanning circle.
CONCLUSIONS: Scan location matching may bridge the gap in RNFL thickness measurements between TD-OCT circular scan data and 3-D SD-OCT scan data, providing follow-up comparability across the two generations of OCTs.

Entities:  

Mesh:

Year:  2009        PMID: 19737886      PMCID: PMC2868471          DOI: 10.1167/iovs.09-4110

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  13 in total

1.  Ophthalmic imaging by spectral optical coherence tomography.

Authors:  Maciej Wojtkowski; Tomasz Bajraszewski; Iwona Gorczyńska; Piotr Targowski; Andrzej Kowalczyk; Wojciech Wasilewski; Czesław Radzewicz
Journal:  Am J Ophthalmol       Date:  2004-09       Impact factor: 5.258

2.  Retinal nerve fiber layer assessment using optical coherence tomography with active optic nerve head tracking.

Authors:  Hiroshi Ishikawa; Michelle L Gabriele; Gadi Wollstein; R Daniel Ferguson; Daniel X Hammer; L Adelina Paunescu; Siobahn A Beaton; Joel S Schuman
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-03       Impact factor: 4.799

3.  Effects of scan circle displacement in optical coherence tomography retinal nerve fibre layer thickness measurement: a RNFL modelling study.

Authors:  C Y L Cheung; C K F Yiu; R N Weinreb; D Lin; H Li; A Y Yung; C P Pang; D S C Lam; C K S Leung
Journal:  Eye (Lond)       Date:  2008-09-19       Impact factor: 3.775

4.  Optical coherence tomography scan circle location and mean retinal nerve fiber layer measurement variability.

Authors:  Michelle L Gabriele; Hiroshi Ishikawa; Gadi Wollstein; Richard A Bilonick; Kelly A Townsend; Larry Kagemann; Maciej Wojtkowski; Vivek J Srinivasan; James G Fujimoto; Jay S Duker; Joel S Schuman
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-06       Impact factor: 4.799

5.  Optical coherence tomography.

Authors:  D Huang; E A Swanson; C P Lin; J S Schuman; W G Stinson; W Chang; M R Hee; T Flotte; K Gregory; C A Puliafito
Journal:  Science       Date:  1991-11-22       Impact factor: 47.728

Review 6.  Optical coherence tomography: a new tool for glaucoma diagnosis.

Authors:  J S Schuman; M R Hee; A V Arya; T Pedut-Kloizman; C A Puliafito; J G Fujimoto; E A Swanson
Journal:  Curr Opin Ophthalmol       Date:  1995-04       Impact factor: 3.761

7.  Quantification of nerve fiber layer thickness in normal and glaucomatous eyes using optical coherence tomography.

Authors:  J S Schuman; M R Hee; C A Puliafito; C Wong; T Pedut-Kloizman; C P Lin; E Hertzmark; J A Izatt; E A Swanson; J G Fujimoto
Journal:  Arch Ophthalmol       Date:  1995-05

8.  Optical coherence tomography longitudinal evaluation of retinal nerve fiber layer thickness in glaucoma.

Authors:  Gadi Wollstein; Joel S Schuman; Lori L Price; Ali Aydin; Paul C Stark; Ellen Hertzmark; Edward Lai; Hiroshi Ishikawa; Cynthia Mattox; James G Fujimoto; Lelia A Paunescu
Journal:  Arch Ophthalmol       Date:  2005-04

9.  Retinal nerve fibre layer thickness measurement reproducibility improved with spectral domain optical coherence tomography.

Authors:  J S Kim; H Ishikawa; K R Sung; J Xu; G Wollstein; R A Bilonick; M L Gabriele; L Kagemann; J S Duker; J G Fujimoto; J S Schuman
Journal:  Br J Ophthalmol       Date:  2009-05-07       Impact factor: 4.638

10.  Agreement between spectral-domain and time-domain OCT for measuring RNFL thickness.

Authors:  G Vizzeri; R N Weinreb; A O Gonzalez-Garcia; C Bowd; F A Medeiros; P A Sample; L M Zangwill
Journal:  Br J Ophthalmol       Date:  2009-03-19       Impact factor: 4.638

View more
  27 in total

1.  Glaucoma research community and FDA look to the future, II: NEI/FDA Glaucoma Clinical Trial Design and Endpoints Symposium: measures of structural change and visual function.

Authors:  Robert N Weinreb; Paul L Kaufman
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-10-04       Impact factor: 4.799

Review 2.  Retinal imaging and image analysis.

Authors:  Michael D Abràmoff; Mona K Garvin; Milan Sonka
Journal:  IEEE Rev Biomed Eng       Date:  2010

3.  Comparison of retinal nerve fiber layer measured by time domain and spectral domain optical coherence tomography in optic neuritis.

Authors:  G Rebolleda; A García-García; H R Won Kim; F J Muñoz-Negrete
Journal:  Eye (Lond)       Date:  2010-12-24       Impact factor: 3.775

Review 4.  Imaging of the retinal nerve fibre layer with spectral domain optical coherence tomography for glaucoma diagnosis.

Authors:  Kyung Rim Sung; Jong S Kim; Gadi Wollstein; Lindsey Folio; Michael S Kook; Joel S Schuman
Journal:  Br J Ophthalmol       Date:  2010-10-28       Impact factor: 4.638

5.  Signal normalization reduces systematic measurement differences between spectral-domain optical coherence tomography devices.

Authors:  Chieh-Li Chen; Hiroshi Ishikawa; Yun Ling; Gadi Wollstein; Richard A Bilonick; Juan Xu; James G Fujimoto; Ian A Sigal; Larry Kagemann; Joel S Schuman
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-11-05       Impact factor: 4.799

6.  Regression Analysis of Optical Coherence Tomography Disc Variables for Glaucoma Diagnosis.

Authors:  Grace M Richter; Xinbo Zhang; Ou Tan; Brian A Francis; Vikas Chopra; David S Greenfield; Rohit Varma; Joel S Schuman; David Huang
Journal:  J Glaucoma       Date:  2016-08       Impact factor: 2.503

Review 7.  Optical coherence tomography: history, current status, and laboratory work.

Authors:  Michelle L Gabriele; Gadi Wollstein; Hiroshi Ishikawa; Larry Kagemann; Juan Xu; Lindsey S Folio; Joel S Schuman
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-04-14       Impact factor: 4.799

Review 8.  The use of SD-OCT in the differential diagnosis of dots, spots and other white retinal lesions.

Authors:  Elena Zaharova; Jerome Sherman
Journal:  Eye Brain       Date:  2011-10-25

9.  Reproducibility of retinal nerve fiber layer thickness measures using eye tracking in children with nonglaucomatous optic neuropathy.

Authors:  Raneem D Rajjoub; Carmelina Trimboli-Heidler; Roger J Packer; Robert A Avery
Journal:  Am J Ophthalmol       Date:  2014-10-02       Impact factor: 5.258

10.  Tracking longitudinal retinal changes in experimental ocular hypertension using the cSLO and spectral domain-OCT.

Authors:  Li Guo; Eduardo M Normando; Shereen Nizari; David Lara; M Francesca Cordeiro
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-08-04       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.